Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.

ABSTRACT:

Background

Loss of function of triggering receptor expressed on myeloid cell 2 (TREM2), a key receptor selectively expressed by microglia in the brain, contributes to the development of Alzheimer's disease (AD). Whether TREM2 levels are pathologically altered during the preclinical phase, and whether cerebrospinal fluid (CSF) soluble TREM2 protein (sTREM2) has a relationship with major pathological processes including Aβ and tau deposition are still unclear.

Methods

According to the NIA-AA criteria, 659 cognitively normal participants from the Chinese Alzheimer's Biomarker and LifestylE (CABLE) cohort were divided into four groups, stage 0 (normal Aβ_1-42, T-tau and P-tau), stage 1 (low Aβ_1-42, normal T-tau and P-tau), stage 2 (low Aβ_1-42 and

SUBMITTER: Ma LZ 

PROVIDER: S-EPMC7149923 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature